

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–65) and Recommended (1–31) International Nonproprietary Names can be found in *Cumulative List No. 8, 1992*. The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs.

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–65) et recommandées (1–31) dans la *Liste récapitulative No. 8, 1992*. Les mentions indiquant les propriétés et les indications des substances sont fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de DCI.

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud como Denominaciones Comunes Internacionales Propuestas. La inclusión de una denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–65) y Recomendadas (1–31) se encuentran reunidas en *Cumulative List No. 8, 1992*. Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI.

## Proposed International Nonproprietary Names: List 72

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 72 Proposed INN not later than 30 June 1995**.

## Dénominations communes internationales proposées: Liste 72

Des observations ou des objections formelles à l'égard des dénominations proposées peuvent être adressées par toute personne au Programme des Dénominations communes internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à compter de la date de leur publication dans *WHO Drug Information*, c'est à dire pour la **Liste 72 de DCI Proposées le 30 juin 1995 au plus tard**.

## Denominaciones Comunes Internacionales Propuestas: Lista 72

Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación en *WHO Drug Information*, es decir, para la **Lista 72 de DCI Propuestas el 30 de junio de 1995 a más tardar**.

|                                                          |                                                                                                                                                    |
|----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Proposed INN</i><br>(Latin, English, French, Spanish) | <i>Chemical name or description: Action and use: Molecular formula</i><br><i>Chemical Abstracts Service (CAS) registry number: Graphic formula</i> |
| <i>DCI Proposée</i>                                      | <i>Nom chimique ou description: Propriétés et indications: Formule brute</i><br><i>Numéro dans le registre du CAS: Formule développée</i>          |
| <i>DCI Propuesta</i>                                     | <i>Nombre químico o descripción: Acción y uso: Fórmula empírica</i><br><i>Número de registro del CAS: Fórmula desarrollada</i>                     |

### acitazanolastum

acitazanolast

3'-(1*H*-tetrazol-5-yl)oxanilic acid  
*antiallergic*

acitazanolast


acide *N*-[3-(1*H*-tétrazol-5-yl)phényl]oxamique  
*antiallergique*

acitazanolast

ácido 3'-(1*H*-tetrazol-5-il)oxanílico  
*antialérgico*

C<sub>9</sub>H<sub>7</sub>N<sub>5</sub>O<sub>3</sub>

114607-46-4



### adefovirum

adefovir

[[2-(6-amino-9*H*-purin-9-yl)ethoxy]methyl]phosphonic acid  
*antiviral*


adéfoviri

acide [[2-(6-amino-9*H*-purin-9-yl)éthoxy]méthyl]phosphonique  
*antiviral*

adefovir

ácido [[2-(6-amino-9*H*-purin-9-yl)etoxi]metil] fosfónico  
*antiviral* $C_8H_{12}N_5O_4P$ 

106941-25-7



afelimomabum

afelimomab

immunoglobulin G 3 (mouse monoclonal LU54107 Fab' fragment  $\gamma$ -chain anti-human tumor necrosis factor  $\alpha$ ), disulfide with mouse monoclonal LU54107  $\kappa$ -chain, dimer  
*immunomodulator*

afélimomab

immunoglobuline G 3 (chaîne  $\gamma$  du fragment Fab' de l'anticorps monoclonal de souris LU54107 anti-facteur de nécrose tumorale  $\alpha$  humain), dimère du disulfure avec la chaîne  $\kappa$  de l'anticorps monoclonal de souris LU54107  
*immunomodulateur*

afelimomab

inmunoglobulina G 3 (cadena  $\gamma$  del fragmento Fab' del anticuerpo monoclonal de ratón LU54107 anti-factor de necrosis tumoral  $\alpha$  humano), dímero del disulfuro con la cadena  $\kappa$  del anticuerpo monoclonal de ratón LU54107  
*immunomodulador*

156227-98-4

alniditanum

alniditan

2-[[3-[[[(*R*)-2-chromanyl]methyl]amino]propyl]amino]-1,4,5,6-tetrahydropyrimidine  
*antimigraine, serotoninine receptor agonist*


alniditan

*N*-[[[(2*R*)-3,4-dihydro-2*H*-chromén-2-yl]méthyl]-*N*'-(1,4,5,6-tétrahydropyrimidin-2-yl)propan-1,3-diyl]diamine  
*antimigraíneux, agoniste de la sérotonine*

alniditan

2-[[3-[[[(*R*)-2-cromanilmetil]amino]propil]amino]-1,4,5,6-tetrahidropirimidina  
*antimigrañoso, agonista de los receptores de la serotonina* $C_{17}H_{26}N_4O$ 

152317-89-0



**anakinrum**

anakinra

*N*<sup>2</sup>-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)  
*immunomodulator, interleukin-1 receptor antagonist*

anakinra

*N*<sup>2</sup>-L-méthionylantagoniste du récepteur de l'interleukine-1 (isoforme x humaine réduite)  
*immunomodulateur, antagoniste du récepteur de l'interleukine-1*

anakinra

*N*<sup>2</sup>-L-metionil antagonista del receptor de interleukina 1 (isoforma x reducida, humana)  
*immunomodulador, antagonista del receptor de la interleukina-1*

C<sub>759</sub>H<sub>1186</sub>N<sub>206</sub>O<sub>232</sub>S<sub>10</sub> 143090-92-0

**anastrozolum**

anastrozole

$\alpha,\alpha,\alpha',\alpha'$ -tetramethyl-5-(1*H*-1,2,4-triazol-1-ylmethyl)-*m*-benzenediacetonitrile  
*antineoplastic*


anastrozole

2,2'-diméthyl-2,2'-[5-[(1*H*-1,2,4-triazol-1-yl)méthyl]benzène-1,3-diyl]=  
 dipropanenitrile  
*antinéoplasique*

anastrozol

$\alpha,\alpha,\alpha',\alpha'$ -tetrametil-5-(1*H*-1,2,4-triazol-1-ilmetil)-*m*-bencendiacetonitrilo  
*antineoplásico*

C<sub>17</sub>H<sub>19</sub>N<sub>5</sub> 120511-73-1

**aptiganelum**

aptiganel

1-(*m*-ethylphenyl)-1-methyl-3-(1-naphthyl)guanidine  
*NMDA receptor antagonist*


aptiganel

1-(3-éthylphényl)-1-méthyl-3-(naphtalén-1-yl)guanidine  
*antagoniste des récepteurs du NMDA*

aptiganel

1-(*m*-etilfenil)-1-metil-3-(1-naftil)guanidina  
*antagonista de los receptores de NMDA*

C<sub>20</sub>H<sub>21</sub>N<sub>3</sub> 137159-92-3



**atexakinum alfa**

atexakin alfa

1-(1-L-alanyl-L-proline)interleukin 6 (human clone HGF15 protein moiety reduced), cyclic (44→50), (73→83)-bis(disulfide)  
*immunomodulator*

atexakine alfa

(44→50), (73→83)-bis(disulfure cyclique) de la [1-(1-L-alanyl-L-proline)]=  
interleukine 6 (partie protéique réduite de la substance issue du clone  
humain HGF15)  
*immunomodulateur*

atexakina alfa

1-(1-L-alanil-L-prolina)interleukina 6 (fracción proteica reducida del clon  
humano HGF15), bis(disulfuro)cíclico (44→50), (73→83)  
*inmunomodulador*

C<sub>917</sub>H<sub>1483</sub>N<sub>255</sub>O<sub>288</sub>S<sub>9</sub> 143631-61-2

**atibepronum**

atibeprone

7-[(5-isopropyl-1,3,4-thiadiazol-2-yl)methoxy]-3,4-dimethylcoumarin  
*antidepressant*


atibéprone

3,4-diméthyl-7-[[5-(1-méthyléthyl)-1,3,4-thiadiazol-2-yl]méthoxy]-2H-  
chromén-2-one  
*antidépresseur*

atibeprona

7-[[5-isopropil-1,3,4-tiadiazol-2-il]metoxi]-3,4-dimetilcumarina  
*antidepresivo*

C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>S 153420-96-3

**azimilidum**

azimilide

1-[[5-(p-chlorophenyl)furfurylidene]amino]-3-[4-(4-methyl-1-  
piperazinyl)butyl]hydantoin  
*antiarrhythmic*


azimilide

1-[[[5-(4-chlorophényl)furan-2-yl]méthylène]amino]-3-[4-(4-méthylpipérazin-  
1-yl)butyl]imidazolidine-2,4-dione  
*antiarythmique*

azimilida

1-[[5-(p-clorofenil)furfuriliden]amino]-3-[4-(4-metil-1-piperazinil)butil]=  
hidantoína  
*antiarrítmico*

C<sub>23</sub>H<sub>28</sub>ClN<sub>5</sub>O<sub>3</sub> 149908-53-2



**basifunginum**

basifungin

*N*-[(2*R*,3*R*)-2-hydroxy-3-methylvaleryl]-*N*-methyl-L-valyl-L-phenylalanyl-*N*-methyl-L-phenylalanyl-L-prolyl-L-alloisoleucyl-*N*-methyl-L-valyl-L-leucyl-3-hydroxy-*N*-methyl-L-valine  $\alpha_1$ -lactone  
*antifungal*

basifungine


$\alpha_1$ -lactone de la [*N*-[(2*R*,3*R*)-2-hydroxy-3-méthylpentanoyl]-*N*-méthyl-L-valyl]-L-phénylalanyl-(*N*-méthyl-L-phénylalanyl)-L-prolyl-L-allo-isoleucyl-(*N*-méthyl-L-valyl)-L-leucyl-(3-hydroxy-*N*-méthyl-L-valine)  
*antifongique*

basifungina

*N*-[(2*R*,3*R*)-2-hidroxi-3-metilvaleril]-*N*-metil-L-valil-L-fenilalanil-*N*-metil-L-fenilalanil-L-proil-L-alloisoleucil-*N*-metil-L-valil-L-leucil-3-hidroxi-*N*-metil-L-valina  $\alpha_1$ -lactona  
*antifúngico*

C<sub>60</sub>H<sub>92</sub>N<sub>8</sub>O<sub>11</sub>

127785-64-2

**bervastatinum**

bervastatin

ethyl (±)-(3*R*<sup>\*</sup>,5*S*<sup>\*</sup>,6*E*)-7-[4-(*p*-fluorophenyl)spiro[2*H*-1-benzopyran-2,1'-cyclopentan]-3-yl]-3,5-dihydroxy-6-heptenoate  
*antihyperlipidaemic, HMG-CoA reductase inhibitor*

bervastatine


(±)-(6*E*)-(3*RS*,5*SR*)-7-[4-(4-fluorophényl)spiro[2*H*-chromène-2,1'-cyclopentane]-3-yl]-3,5-dihydroxyhept-6-énoate d'éthyle  
*hypolipémiant, inhibiteur de la HMG-CoA réductase*

bervastatina

(±)-(3*R*<sup>\*</sup>,5*S*<sup>\*</sup>,6*E*)-7-[4-(*p*-fluorofenil)espiro[2*H*-1-benzopirán-2,1'-ciclopentan]-3-yl]-3,5-dihidroxi-6-heptenoato de etilo  
*antihiperlipémico, inhibidor de la reductase de la HMG-CoA*

C<sub>28</sub>H<sub>31</sub>FO<sub>5</sub>

132017-01-7



and enantiomer  
et énantiomère  
y enantiómero

**betasizofiranum**

betasizofiran

scleroglucan or poly[→3(O-β-D-glucopyranosyl-(1→3)-O-β-D-glucopyranosyl-(1→6))-O-β-D-glucopyranosyl-(1→3)-O-β-D-glucopyranosyl-(1→)] produced by *Sclerotium rolfsii*; relative molecular mass is about  $5.10^6$   
*laxative*

bétasizofiran


scléroglycane ou poly[→3(O-β-D-glucopyranosyl-(1→3)-O-β-D-glucopyranosyl-(1→6))-O-β-D-glucopyranosyl-(1→3)-O-β-D-glucopyranosyl-(1→)] produit par *Sclerotium rolfsii*; la masse moléculaire relative est voisine de  $5.10^6$   
*laxatif*

betasizofiran

escleroglucano ó poli[→3(O-β-D-glucopiranosil-(1→3)-O-β-D-glucopiranosil-(1→6))-O-β-D-glucopiranosil-(1→3)-O-β-D-glucopiranosil-(1→)] producido por *Sclerotium rolfsii*; la masa molecular relativa es aproximadamente de  $5.10^6$   
*laxante*

 $(C_{24}H_{40}O_{20})_n$ 

39464-87-4

**bivalirudinum**

bivalirudin

D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucine  
*anticoagulant*

bivalirudine

D-phénylalanil-L-prolil-L-arginil-L-prolil-glycyl-glycyl-glycyl-glycyl-L-asparaginyl-glycyl-L-α-aspartyl-L-phénylalanil-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolil-L-α-glutamyl-L-α-glutamyl-L-tyrosil-L-leucine  
*anticoagulant*

bivalirudina

D-fenilalanil-L-prolil-L-arginil-L-prolilglicilglicilglicilglicil-L-asparaginilglicil-L-α-aspartil-L-fenilalanil-L-α-glutamil-L-α-glutamil-L-isoleucil-L-prolil-L-α-glutamil-L-α-glutamil-L-tirosil-L-leucina  
*anticoagulante*

 $C_{98}H_{138}N_{24}O_{33}$ 

128270-60-0

H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-

Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH

**capecitabinum**

capecitabine

1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-  
4-pyrimidinecarbamic acid  
*antineoplastic*

capécitabine


acide [1-(5-désoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-  
4-yl]carbamique  
*antineoplasique*

capecitabina

ácido 1-(5-desoxi-β-D-ribofuranosil)-5-fluoro-1,2-dihidro-2-oxo-  
4-pirimidincarbámico  
*antineoplásico*

C<sub>10</sub>H<sub>12</sub>FN<sub>3</sub>O<sub>6</sub>

158798-73-3

**cartasteinum**

cartasteine

(S)-3-[N-[(R)-2-mercaptopropionyl]glycyl]-4-thiazolidinecarboxylic acid  
*mucohydrotic*

cartastéine


acide (4S)-3-[2-[[[(2R)-2-mercaptopropanoyl]amino]acétyl]thiazolidine-  
4-carboxylique  
*mucohydrotique*

cartasteina

ácido (S)-3-[N-[(R)-2-mercaptopropionil]glicil]-4-tiazolidinecarboxílico  
*mucohidrótico*

C<sub>9</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub>

149079-51-6

**cidofovirum**

cidofovir

[[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]=  
phosphonic acid  
*antiviral*

cidofovir

acide [[[(1S)-2-(4-amino-2-oxypyrimidin-1(2H)-yl)-1-(hydroxyméthyl)éthoxy]=  
méthyl]phosphonique  
*antiviral*




cidofovir

ácido [[[*S*]-2-(4-amino-2-oxo-1(2*H*)-pirimidinil)-1-(hidroximetil)etoxi]metil]=  
fosfónico  
*antiviral*

C<sub>8</sub>H<sub>14</sub>N<sub>3</sub>O<sub>6</sub>P

113852-37-2

**cromoglicas lisetilum**

cromoglicate lisetil

diethyl 5,5'-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-4*H*-1-benzopyran-  
2-carboxylate], ester with L-lysine  
*antiallergic, antiasthmatic*

cromoglicate lisétíl


(+)-5,5'-[[2-[(2*S*)-2,6-diaminohexanoyl]oxy]propane-1,3-diyl]dioxy]bis(4-oxo-  
4*H*-chromène-2-carboxylate d'éthyle)  
*antiallergique, antiasthmatique*

cromoglicato lisetil

5,5'-[(2-hidroxitrimetileno)dioxi]bis[4-oxo-4*H*-1-benzopirano-  
2-carboxilato] de dietilo, éster con L-lisina  
*antialérgico, antiasmático*

C<sub>33</sub>H<sub>36</sub>N<sub>2</sub>O<sub>12</sub>

110816-79-0

**ebalzotanum**

ebalzotan

(*R*)-*N*-isopropyl-3-(isopropylpropylamino)-5-chromancarboxamide  
*serotonin receptor agonist*

ébalzotan


(3*R*)-*N*-(1-méthyléthyl)-3-[(1-méthyléthyl)propylamino]-3,4-dihydro-  
2*H*-chromène-5-carboxamide  
*agoniste de la sérotonine*

ebalzotan

(*R*)-*N*-isopropil-3-(isopropilpropilamino)-5-cromancarboxamida  
*agonista de los receptores de la serotonina*

$C_{19}H_{30}N_2O_2$ 

149494-37-1

**elisartanum**

elisartan

(±)-1-hydroxyethyl 2-butyl-4-chloro-1-[p-(α-1H-tetrazol-5-yl)phenyl]benzyl=imidazole-5-carboxylate, ethyl carbonate (ester)  
angiotensin II receptor antagonist

élisartan


2-butyl-4-chloro-1-[4-[2-(1H-tétrazol-5-yl)phényl]benzyl]-1H-imidazole-5-carboxylate de (RS)-1-[(éthoxycarbonyl)oxy]éthyle  
antagoniste du récepteur de l'angiotensine II

elisartan

(±)-2-butil-4-cloro-1-[p-(α-1H-tetrazol-5-ilfenil)benzil]imidazole-5-carboxilato,etil carbonato de 1-hidroxietilo (éster)  
antagonista del receptor de angiotensina II

 $C_{27}H_{29}ClN_5O_5$ 

158682-68-9



and enantiomer  
et énantiomère  
y enantiómero

**epoetinum epsilon**

epoetin epsilon

1-165-erythropoietin (human clone λHEPOFL13 protein moiety), glycoform ε  
antianæmic

époétine epsilon

1-165-érythropoïétine (partie protéique du clone humain λHEPOFL13), forme glycosylée ε  
antianémique

epoetina epsilon

1-165-eritropoietina (fracción proteica del clon humano λHEPOFL13), forma glicosilada ε  
antianémico

 $C_{809}H_{1301}N_{229}O_{240}S_5$ 

154725-65-2

(for non-glycosylated protein)

(pour la protéine non glycosylée)

(fracción proteica no glicosilada)

**eptacogum alfa (activatum)**

eptacog alfa (activated)

blood-coagulation factor VII (human clone  $\lambda$ HVII2463 protein moiety)  
*blood-coagulation factor*

eptacog alfa (activé)

facteur VII de coagulation sanguine (partie protéique de la substance issue du clone humain  $\lambda$ HVII2463)  
*facteur de coagulation sanguine*

eptacog alfa (activado)

factor de coagulación VII (fracción proteica del clon humano  $\lambda$ HVII2463)  
*factor de coagulación sanguínea* $C_{2621}H_{4056}N_{726}O_{612}S_{36}$  102786-52-7**ersentilidum**


ersentilide

4'-[(2*S*)-2-hydroxy-3-[[2-(*p*-imidazol-1-ylphenoxy)ethyl]amino]propoxy]=methanesulfonanilide  
*antiarrhythmic*

ersentilide

*N*-[4-[[[(*S*)-2-hydroxy-3-[[2-[4-(1*H*-imidazol-1-yl)phénoxy]éthyl]amino]propyl]=oxy]phényl]méthanesulfonamide  
*antiarythmique*

ersentilida

4'-[(2*S*)-2-hidroxi-3-[[2-(*p*-imidazol-1-ilfenoxi)etil]amino]propoxi]=metansulfonanilida  
*antiarrítmico* $C_{21}H_{26}N_4O_5S$  125279-79-0**examorelinum**


examorelin

L-histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysineamide  
*growth hormone release stimulating peptide*

examoréline

L-histidyl-(2-méthyl-D-tryptophyl)-L-alanyl-L-tryptophyl-D-phénylalanyl-L-lysineamide  
*peptide stimulant la libération de l'hormone de croissance*

examorelina

L-histidil-2-metil-D-triptofil-L-alanil-L-triptofil-D-fenilalanil-L-lisinamida  
*peptido estimulante de la liberación de la hormona del crecimiento* $C_{47}H_{56}N_{12}O_6$  140703-51-1

**fampridinum**

fampridine

4-aminopyridine  
*potassium channel blocker*


fampridine

pyridin-4-ylamine  
*antagoniste potassique*

fampridina

4-aminopiridina  
*antagonista del potasio*C<sub>5</sub>H<sub>6</sub>N<sub>2</sub>

504-24-5

**fenleutonum**

fenleuton

(±)-1-[3-[*m*-(*p*-fluorophenoxy)phenyl]-1-methyl-2-propynyl]-1-hydroxyurea  
*leukotriene synthesis inhibitor*


fenleuton

(±)-1-[(1*RS*)-3-[3-(4-fluorophénoxy)phényl]-1-méthylprop-2-ynyl]-1-hydroxyurée  
*inhibiteur de la synthèse des leucotriènes*

fenleuton

(±)-1-[3-[*m*-(*p*-fluorofenoxi)fenil]-1-metil-2-propinil]-1-hidroxiurea  
*inhibidor de la síntesis de leucotrienos*C<sub>17</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>3</sub>

141579-54-6

**fodipirum**

fodipir

*N,N'*-ethylenebis[*N*-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridyl]=methyl]glycine] 5,5'-bis(dihydrogenphosphate)  
*diagnostic agent*

fodipir


*N,N'*-éthane-1,2-diylbis[*N*-[[3-hydroxy-2-méthyl-5-[(phosphonooxy)méthyl]=pyridin-4-yl]méthyl]glycine]  
*produit à usage diagnostique*

fodipir

*N,N'*-etilenbis[*N*-[[3-hidroxi-5-(hidroximetil)-2-metil-4-piridil]=metil]glicina] 5,5'-bis(dihidrógenofosfato)  
*agente de diagnóstico*

C<sub>22</sub>H<sub>32</sub>N<sub>4</sub>O<sub>14</sub>P<sub>2</sub>

118248-91-2

**fradafibanum**

fradafiban

(3*S*,5*S*)-5-[[[4'-amidino-4-biphenyl]oxy]methyl]-2-oxo-3-pyrrolidineacetic acid  
fibrinogen receptor antagonist

fradafiban


acide 2-[[[3*S*,5*S*)-5-[[[4'-amidinobiphényl-4-yl]oxy]méthyl]-2-oxopyrrolidin-3-yl]acétique  
antagoniste du récepteur du fibrinogène

fradafiban

ácido (3*S*,5*S*)-5-[[[4'-amidino-4-bifenilil]oxi]metil]-2-oxo-3-pirrolidinacético  
antagonista del receptor del fibrinógeno

C<sub>20</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>

148396-36-5

**galdansetronum**

galdansetron

(+)-(3*R*)-2,3-dihydro-9-methyl-3-[(5-methylimidazol-4-yl)methyl]carbazol-4(1*H*)-one  
serotonin receptor antagonist

galdansétron


(+)-(3*R*)-9-méthyl-3-[(5-méthyl-1*H*-imidazol-4-yl)méthyl]-1,2,3,9-tétrahydro-4*H*-carbazol-4-one  
antagoniste de la sérotonine

galdansetron

(+)-(3*R*)-2,3-dihidro-9-metil-3-[(5-metilimidazol-4-il)metil]carbazol-4(1*H*)-ona  
antagonista de los receptores de la serotonina

C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O

116684-92-5



**goralatidum**

goralatide

1-[*N*<sup>2</sup>-[*N*-(*N*-acetyl-L-seryl)-L-α-aspartyl]-L-lysyl]-L-proline  
*immunomodulator*

goralatide


(*N*-acétyl-L-séryl)-L-α-aspartyl-L-lysyl-L-proline  
*immunomodulateur*

goralatida

1-[*N*<sup>2</sup>-[*N*-(*N*-acetil-L-seril)-L-α-aspartil]-L-lisil]-L-prolina  
*immunomodulador*

C<sub>20</sub>H<sub>33</sub>N<sub>5</sub>O<sub>9</sub>

120081-14-3

**imiglucerasum**

imiglucerase

495-L-histidineglucosylceramidase (human placenta isoenzyme protein moiety)  
*enzyme*

imiglucérase

[495-L-histidine]glucosylcéramidase (partie protéique d'isoenzyme de placenta humain)  
*enzyme*

imiglucerasa

495-L-histidinaglicosilceramidasa (isoenzima de placenta humana, fracción proteica)  
*enzima*

C<sub>2532</sub>H<sub>3843</sub>N<sub>871</sub>O<sub>711</sub>S<sub>16</sub> 154248-97-2**inogatranum**

inogatran

*N*-[(1*R*)-2-cyclohexyl-1-[(2*S*)-2-[(3-guanidinopropyl)carbamoyl]piperidino]=carbonyl]ethyl]glycine  
*thrombin inhibitor*

inogatran


acide 2-[[[(1*R*)-2-(cyclohexylméthyl)-2-[(2*S*)-2-[(3-guanidinopropyl)amino]=carbonyl]pipéridin-1-yl]-2-oxoéthyl]amino]acétique  
*inhibiteur de la thrombine*

inogatran

*N*-[(1*R*)-2-ciclohexil-1-[(2*S*)-2-[(3-guanidinopropil)carbamoiil]piperidino]=carbonil]etil]glicina  
*inhibidor de la trombina*

C<sub>21</sub>H<sub>38</sub>N<sub>6</sub>O<sub>4</sub>

155415-08-0

**insulinum lisprum**

insulin lispro

28<sup>B</sup>-L-lysine-29<sup>B</sup>-L-prolineinsulin (human)  
*antidiabetic*

insuline lispro

[28<sup>B</sup>-L-lysine-29<sup>B</sup>-L-proline]insuline humaine  
*antidiabétique*

insulina lispro

28<sup>B</sup>-L-lisina-29<sup>B</sup>-L-prolinainsulina (humana)  
*antidiabético*C<sub>257</sub>H<sub>383</sub>N<sub>65</sub>O<sub>77</sub>S<sub>6</sub>

133107-64-9

**lamifibanum**

lamifiban

[[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidyl]oxy]acetic acid  
*fibrinogen receptor antagonist*


lamifiban

acide 2-[[1-[(2S)-2-[(4-amidinobenzoyl)amino]-3-(4-hydroxyphényl)=  
propanoyl]pipéridin-4-yl]oxy]acétique  
*antagoniste du récepteur du fibrinogène*

lamifiban

àcido[[1-[N-(p-amidinobenzoyl)-L-tirosil]-4-piperidil]oxi] acético  
*antagonista del receptor del fibrinogénico*C<sub>24</sub>H<sub>28</sub>N<sub>4</sub>O<sub>6</sub>

144412-49-7



**lanperisonum**

lanperisone

(-)-(R)-2-methyl-3-(1-pyrrolidinyl)-4'-(trifluoromethyl)propiofenone  
*central muscle relaxant*

lanpérisonne


(-)-(2R)-2-méthyl-3-(pyrrolidin-1-yl)-1-[4-(trifluorométhyl)phényl]propan-1-one  
*myorelaxant central*

lanperisona

(-)-(R)-2-metil-3-(1-pirrolidinil)-4'-(trifluorometil)propiofenona  
*miorelajante central*

C<sub>15</sub>H<sub>18</sub>F<sub>3</sub>NO

116287-14-0

**lanprostonum**

lanprostón


(Z)-7-[(1R,2R,3R,5S)-2-[(E)-2-[2-[(m-chlorophenoxy)methyl]-1,3-dioxolan-2-yl]vinyl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid  
*luteotropic agent (vet.)*

lanprostone

acide (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-2-[2-[(3-chlorophénoxy)méthyl]-1,3-dioxolan-2-yl]éthényl]-3,5-dihydroxycyclopentyl]hept-5-énoïque  
*agent lutéotrope (vét.)*

lanprostón

ácido (Z)-7-[(1R,2R,3R,5S)-2-[(1E)-2-[2-[(m-clorofenoxi)metil]-1,3-dioxolan-2-il]vinil]-3,5-dihidroxiciclopentil]-5-heptenoico  
*luteotrópico (vet.)*

C<sub>24</sub>H<sub>31</sub>ClO<sub>7</sub>**lenerceptum**

lenercept

1-182-tumor necrosis factor receptor (human reduced), (182→104')-protein with 104-330-immunoglobulin G 1 (human clone pTJ5 Cγ 1 reduced)  
*tumor necrosis factor antagonist*

lénercept

1-182-récepteur du facteur de nécrose tumorale (humain réduit), (182→104')-protéine avec la 104-330-immunoglobuline G 1 (clone humain pTJ5 Cγ 1 réduit)  
*antagoniste du facteur de nécrose tumorale*

lenercept

1-182-receptor del factor de necrosis tumoral (humano reducido), (182→104')-proteína con la 104-330-inmunoglobulina G 1 (clon humano pTJ5 Cγ 1 reducido)  
*antagonista del factor de necrosis tumoral*

C<sub>1993</sub>H<sub>3112</sub>N<sub>562</sub>O<sub>624</sub>S<sub>34</sub> 156679-34-4



**levosemotiadilum**

levosemotiadil

(-)-(S)-2-[5-methoxy-2-[3-[methyl[2-[3,4-(methylenedioxy)phenoxy]ethyl]=amino]propoxy]phenyl]-4-methyl-2*H*-1,4-benzothiazin-3(4*H*)-one  
*antiarrhythmic*

lévosémotiadiil


(-)-(2*S*)-2-[2-[[3-[[2-(1,3-benzodioxol-5-yloxy)éthyl]méthylamino]propyl]oxy]-5-méthoxyphényl]-4-méthyl-2*H*-1,4-benzothiazin-3(4*H*)-one  
*antiarythmique*

levosemotiadil

(-)-(S)-2-[5-metoxi-2-[3-[metil[2-[3,4-(metilenodioxil)fenoxi]etil]=amino]propoxi]fenil]-4-metil-2*H*-1,4-benzotiazin-3(4*H*)-ona  
*antiarritmico*

C<sub>29</sub>H<sub>32</sub>N<sub>2</sub>O<sub>6</sub>S

116476-16-5

**lirequinilum**

lirequinil

(3*S*)-1-[(10-chloro-6,7-dihydro-4-oxo-3-phenyl-4*H*-benzo[*a*]quinolizin-1-yl)=carbonyl]-3-ethoxypyrrolidine  
*hypnotic*

lirequinil


(3*S*)-1-[(10-chloro-4-oxo-3-phényl-6,7-dihydro-4*H*-benzo[*a*]quinolizin-1-yl)=carbonyl]-3-éthoxypyrrolidine  
*hypnotique*

lirequinilo

(3*S*)-1-[(10-cloro-6,7-dihidro-4-oxo-3-fenil-4*H*-benzo[*a*]quinolizin-1-il)=carbonil]-3-etoxipirrolidina  
*hipnótico*

C<sub>26</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>3</sub>

143943-73-1



**lisofyllinum**

lisofylline

1-[(*R*)-5-hydroxyhexyl]theobromine  
*non-steroidal anti-inflammatory*


lisofylline

1-[(5*R*)-5-hydroxyhexyl]-3,7-diméthyl-3,7-dihydro-1*H*-purin-2,6-dione  
*anti-inflammatoire non-stéroïdien*

lisofilina

1-[(*R*)-5-hidroxiheksil]teobromina  
*antiinflamatorio no esteroideo* $C_{13}H_{20}N_4O_3$ 

100324-81-0

**lobucavirum**

lobucavir

9-[(1*R*,2*R*,3*S*)-2,3-bis(hydroxymethyl)cyclobutyl]guanine  
*antiviral*


lobucavir

2-amino-9-[(1*R*,2*R*,3*S*)-2,3-bis(hydroxyméthyl)cyclobutyl]-1,9-dihydro-6*H*-purin-6-one  
*antiviral*

lobucavir

9-[(1*R*,2*R*,3*S*)-2,3-bis(hidroxi metil) ciclobutil]guanina  
*antiviral* $C_{11}H_{15}N_5O_3$ 

127759-89-1

**mangafodipirum**

mangafodipir

hexahydrogen (OC-6-13)-[[*N,N'*-ethylenebis[*N*-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridyl]methyl]glycine] 5,5'-bis(phosphato)]](8-)) manganate(6-)  
*diagnostic agent*

mangafodipir


(OC-6-13)-hexahidrógeno[[*N,N'*-ethane-1,2-diylbis[*N*-[[3-hidroxi-2-méthyl-5-[(phosphonooxy)méthyl]pyridin-4-yl]méthyl]glycinato]](8-))manganate(6-))  
*produit à usage diagnostique*

mangafodipir

hexahidrógeno (OC-6-13)-[[*N,N'*-etilenbis[*N*-[[3-hidroxi-5-(hidroximetil)-2-metil-4-piridil]metil]glicina] 5,5'-bis(fosfato)]](8-))manganato(6-))  
*agente de diagnóstico*

$C_{22}H_{30}MnN_4O_{14}P_2$ 

155319-91-8

**mapinastinum**

mapinastine

1-(2-ethoxyethyl)-2-[[4-(4-pyrazol-1-ylbutyl)-1-piperazinyl]methyl]=  
benzimidazole*antihistaminic, antiallergic*


mapinastine

1-(2-éthoxyéthyl)-2-[[4-(4-(1*H*-pyrazol-1-yl)butyl]pipérazin-1-yl)méthyl]-1*H*-  
benzimidazole*antihistaminique, antiallergique*

mapinastina

1-(2-etoxietil)-2-[[4-(4-pirazol-1-ilbutil)-1-piperazini]metil]bencimidazol  
*antihistamínico, antialérgico* $C_{23}H_{34}N_6O$ 

140945-32-0

**marsidominum**

marsidomine

3-(*cis*-2,6-dimethylpiperidino)sydnone imine  
*antianginal*


marsidomine

3-(*cis*-2,6-diméthylpipéridin-1-yl)sydnone imine  
*antiangoreux*

marsidomina

3-(*cis*-2,6-dimetilpiperidino)sidnona imina  
*antianginoso* $C_9H_{16}N_4O$ 

137500-42-6



**mazapertinum**

mazapertine

1-[ $\alpha$ -[4-(*o*-isopropoxyphenyl)-1-piperazinyl]-*m*-toluoyl]piperidine  
*antipsychotic, dopamine D<sub>2</sub> receptor antagonist*


mazapertine

1-[3-[[4-[2-(1-méthyléthoxy)phényl]pipérazin-1-yl]méthyl]benzoyl]pipéridine  
*psychotrope, antagoniste du récepteur D<sub>2</sub> de la dopamine*

mazapertina

1-[ $\alpha$ -[4-(*o*-isopropoxifenil)-1-piperazinil]-*m*-toluolil]piperidina  
*antipsicótico, antagonista del receptor D<sub>2</sub> de la dopamina*C<sub>26</sub>H<sub>35</sub>N<sub>3</sub>O<sub>2</sub>

134208-17-6

**mibefradilum**

mibefradil

(1*S*,2*S*)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1- isopropyl-2-naphthyl methoxyacetate  
*calcium channel blocker*


mibéfradil

2-méthoxyacétate de (1*S*,2*S*)-2-[2-[[3-(1*H*-benzimidazol-2-yl)propyl]méthylamino]éthyl]-6-fluoro-1-(1-méthyléthyl)-1,2,3,4-tétrahydronaphtalén-2-yle  
*antagoniste calcique*

mibefradil

(1*S*,2*S*)-2-[2-[[3-(2-benzimidazolil)propil]metilamino]etil]-6-fluoro-1,2,3,4-tetrahydro-1-isopropil-2-naftil metoxiacetato  
*antagonista del calcio*C<sub>29</sub>H<sub>35</sub>FN<sub>3</sub>O<sub>3</sub>

116644-53-2

**mirisetrinum**

mirisetrone

1-cyclohexyl-1,4-dihydro-4-oxo-*N*-1 $\alpha$ H,5 $\alpha$ H-tropan-3 $\alpha$ -yl-3-quinoline=carboxamide  
*anxiolytic*

mirisétron


1-cyclohexyl-*N*-{[1*R*,3*r*,5*S*]-8-méthyl-8-azabicyclo[3.2.1]oct-3-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxamide  
*anxiolytique*

mirisetrone

1-ciclohexil-1,4-dihidro-4-oxo-*N*-1 $\alpha$ H,5 $\alpha$ H-tropan-3 $\alpha$ -il-3-quinolina=carboxamida  
*ansiolítico*

$C_{24}H_{31}N_3O_2$ 

135905-89-4

**mobenakinum**

mobenakin

71-L-serineinterleukin 1 $\beta$  (human clone pIL-1-14 reduced)  
*immunomodulator*

mobénakine

[71-L-sérine]interleukine 1 $\beta$  (clone humain pIL-1-14, réduite)  
*immunomodulateur*

mobenakina

71-L-serinainterleuquina 1 $\beta$  (clon humano pIL-1-14 reducido)  
*immunomodador* $C_{773}H_{1219}N_{201}O_{238}S_7$  124146-64-1**moroctocogum alfa**

moroctocog alfa

(1-742)-(1637-1648)-blood-coagulation factor VIII (human reduced) complex  
with 1649-2332-blood-coagulation factor VIII (human reduced)  
*blood-coagulation factor*

moroctocog alfa

complexe du (1-742)-(1637-1648)-facteur VIII de coagulation sanguine  
(humain réduit) avec le 1649-2332-facteur VIII de coagulation sanguine  
(humain réduit)  
*facteur de coagulation sanguine*

moroctocog alfa

(1-742)-(1637-1648)-factor de coagulación VIII (humano reducido) complejo  
con 1649-2332-factor de coagulación VIII (humano reducido)  
*factor de coagulación sanguínea* $C_{3953}H_{6020}N_{1040}O_{1158}S_{29}$ +  
 $C_{3553}H_{5412}N_{956}O_{1028}S_{33}$ **muplestimum**

muplestim

interleukin 3 (human protein moiety reduced)  
*immunomodulator*

muplestim

interleukine 3 (partie protéique humaine réduite)  
*immunomodulateur*

muplestim

interleukina 3 (fracción proteica reducida humana)  
*immunomodador* $C_{670}H_{1076}N_{186}O_{199}S_5$  113315-09-6

**napsagatranum**

napsagatran

*N*-[*N*<sup>4</sup>-[[[(3*S*)-1-amidino-3-piperidyl]methyl]-*N*<sup>2</sup>-(2-naphthylsulfonyl)-*L*-asparaginy]]-*N*-cyclopropylglycine  
*thrombin inhibitor*

napsagatran


acide 2-[[[(2*S*)-4-[[[(3*S*)-1-amidinopipéridin-3-yl]méthyl]amino]-2-[[naph= talén-2-yl)sulfonyl]amino]-4-oxobutanoyl](cyclopropyl)amino]acétique  
*inhibiteur de la thrombine*

napsagatran

*N*-[*N*<sup>4</sup>-[[[(3*S*)-1-amidino-3-piperidil]metil]-*N*<sup>2</sup>-(2-naftilsulfonyl)-*L*-asparaginil]-*N*-ciclopropilglicina  
*inhibidor de la trombina*

C<sub>26</sub>H<sub>34</sub>N<sub>6</sub>O<sub>6</sub>S

154397-77-0

**netivudinum**

netivudine

1-β-D-arabinofuranosyl-5-(1-propynyl)uracil  
*antiviral*

nétivudine


1-(β-D-arabinofuranosyl)-5-(prop-1-ynyl)pyrimidine-2,4(1*H*,3*H*)-dione  
*antiviral*

netivudina

1-β-D-arabinofuranosil-5-(1-propinil)uracilo  
*antiviral*

C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>6</sub>

84558-93-0

**nicanartinum**

nicanartine

2,6-di-*tert*-butyl-4-[3-(3-pyridylmethoxy)propyl]phenol  
*antihyperlipidaemic*


nicanartine

2,6-bis(1,1-diméthyléthyl)-4-[3-[(pyridin-3-yl)méthoxy]propyl]phénol  
*hypolipémiant*

nicanartina

2,6-di-*tert*-butyl-4-[3-(3-piridilmetoxi)propil]fenol  
*anthiperlipémico*C<sub>23</sub>H<sub>33</sub>NO<sub>2</sub>

150443-71-3



nicotredolum

nicotredole

*N*-(2-indol-3-ylethyl)nicotinamide  
*non-steroidal anti-inflammatory (vet.)*


nicotrédone

*N*-[2-(1*H*-indol-3-yl)éthyl]pyridine-3-carboxamide  
*anti-inflammatoire non-stéroïdien (vét.)*

nicotredol

*N*-(2-indol-3-iletil)nicotinamida  
*antiinflamatorio no esteroideo (vet.)*C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>O

29876-14-0



ocinaplonum

ocinaplon

2-pyridyl 7-(4-pyridyl)pyrazolo[1,5-*a*]pyrimidin-3-yl ketone  
*anxiolytic*


ocinaplon

(pyridin-2-yl)[7-(pyridin-4-yl)pyrazolo[1,5-*a*]pyrimidin-3-yl]méthanone  
*anxiolytique*

ocinaplon

2-piridil 7-(4-piridil)pirazolo[1,5-*a*]pirimidin-3-il cetona  
*ansiolítico*C<sub>17</sub>H<sub>11</sub>N<sub>5</sub>O

96604-21-6




olopatadinum


olopatadine

11-[(*Z*)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[*b,e*]oxepin-2-acetic acid  
*antiallergic*

|             |                                                                                                                                              |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| olopatadine | acide 2-[11-[(1 <i>Z</i> )-3-(diméthylamino)propylidène]-6,11-dihydrodibenzo=<br>[ <i>b,e</i> ]oxépin-2-yl]acétique<br><i>antiallergique</i> |
| olopatadina | ácido 11-[( <i>Z</i> )-3-(dimetilamino)propiliden]-6,11-dihidrodibenz[ <i>b,e</i> ]oxepin-2-<br>acético<br><i>antialérgico</i>               |
|             | $C_{21}H_{23}NO_3$ 113806-05-6                                                                                                               |

**ontazolastum**

|            |                                                                                                             |
|------------|-------------------------------------------------------------------------------------------------------------|
| ontazolast | 2-[[( <i>S</i> )-2-cyclohexyl-1-(2-pyridyl)éthyl]amino]-5-méthylbenzoxazole<br><i>antiasthmatic</i>         |
| ontazolast | [(1 <i>S</i> )-2-cyclohexyl-1-(pyridin-2-yl)éthyl][(5-méthylbenzoxazol-2-yl)amine<br><i>antiasthmatique</i> |
| ontazolast | 2-[[( <i>S</i> )-2-ciclohexil-1-(2-píridil)etil]amino]-5-metilbenzoxazol<br><i>antasmático</i>              |
|            | $C_{21}H_{25}N_3O$ 147432-77-7                                                                              |

**orientiparcinum**

|               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| orientiparcin | a mixture of orienticine A and orienticine D,<br>orienticine A (major component):<br>(-)-(3 <i>S</i> ,6 <i>R</i> ,7 <i>R</i> ,22 <i>R</i> ,23 <i>S</i> ,26 <i>S</i> ,36 <i>R</i> ,38 <i>aR</i> )-22-[(3-amino-2,3,6-trideoxy-3- <i>C</i> -<br>methyl- $\alpha$ -L- <i>arabino</i> -hexopyranosyl)oxy]-44-[[2- <i>O</i> -(3-amino-2,3,6-trideoxy-3-<br><i>C</i> -methyl- $\alpha$ -L- <i>arabino</i> -hexopyranosyl)- $\beta$ -D-glucopyranosyl]oxy]-3-<br>(carbamoylmethyl)-19-chloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38 <i>a</i> -<br>tetradecahydro-7,28,30,32-tetrahydroxy-6-[(2 <i>R</i> )-4-methyl-2-<br>(methylamino)valeramido-2,5,24,38,39-pentaoxo-22 <i>H</i> -8,11:18,21-dietheno-<br>23,36-(iminomethano)-13,16:31,35-dimetheno-1 <i>H</i> ,16 <i>H</i> -<br>[1,6,9]oxadiazacyclohexadecino[4,5- <i>m</i> ][10,2,16]benzoxadiaz=<br>cyclotetracosine-26-carboxylic acid |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|



orienticine D (minor component) :

(-)-(3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38*aR*)-22-[(3-amino-2,3,6-trideoxy-3-*C*-methyl- $\alpha$ -*L*-arabino-hexopyranosyl)oxy]-44-[[2-*O*-(3-amino-2,3,6-trideoxy-3-*C*-methyl- $\alpha$ -*L*-arabino-hexopyranosyl)- $\beta$ -*D*-glucopyranosyl]oxy]-3-(carbamoylmethyl)-19-chloro-6-[(2*R*)-2-(dimethylamino)-4-methylvaleramido]-2,3,4,5,6,7,23,24,25,26,36,37,38,38*a*-tetradecahydro-7,28,30,32-tetrahydroxy-2,5,24,38,39-pentaoxo-22*H*-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1*H*,16*H*-[1,6,9]oxadiazacyclohexadecino[4,5-*m*][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid  
*antibacterial (vet.)*

orientiparcine

mélange d'orienticine A et d'orienticine D,

orienticine A (constituant principal):

acide (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38*aR*)-22-[(3-amino-3-*C*-méthyl-2,3,6-tridésoxy- $\alpha$ -*L*-arabino-hexopyranosyl)oxy]-44-[[2-*O*-(3-amino-3-*C*-méthyl-2,3,6-tridésoxy- $\alpha$ -*L*-arabino-hexopyranosyl)- $\beta$ -*D*-glucopyranosyl]oxy]-3-(carbamoylméthyl)-19-chloro-7,28,30,32-tétrahydroxy-6-[[(*R*)-4-méthyl-2-(méthylamino)pentanoyl]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38*a*-tétradécahydro-8,11:18,21-diéthéno-23,36-(iminométhano)-22*H*-13,16:31,35-diméthéno-1*H*,13*H*-[1,6,9]oxadiazacyclohexadécino[4,5-*m*][10,2,16]benzoxadiazacyclotétracosène-26-carboxylique

orienticine D (constituant secondaire):

acide (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38*aR*)-22-[(3-amino-3-*C*-méthyl-2,3,6-tridésoxy- $\alpha$ -*L*-arabino-hexopyranosyl)oxy]-44-[[2-*O*-(3-amino-3-*C*-méthyl-2,3,6-tridésoxy- $\alpha$ -*L*-arabino-hexopyranosyl)- $\beta$ -*D*-glucopyranosyl]oxy]-3-(carbamoylméthyl)-19-chloro-7,28,30,32-tétrahydroxy-6-[[(*R*)-2-(diméthylamino)-4-méthylpentanoyl]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38*a*-tétradécahydro-8,11:18,21-diéthéno-23,36-(iminométhano)-22*H*-13,16:31,35-diméthéno-1*H*,13*H*-[1,6,9]oxadiazacyclohexadécino[4,5-*m*][10,2,16]benzoxadiazacyclotétracosène-26-carboxylique

*antibactérien (vét.)*

orientiparcina

mezcla de orienticina A y de orienticina D,

orienticina A (constituyente principal):

ácido (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38*aR*)-22-[(3-amino-3-*C*-metil-2,3,6-tridesoxi- $\alpha$ -*L*-arabino-hexopiranosil)oxi]-44-[[2-*O*-(3-amino-3-*C*-metil-2,3,6-tridesoxi- $\alpha$ -*L*-arabino-hexopiranosil)- $\beta$ -*D*-glucopiranosil]oxi]-3-(carbamoilmetil)-19-cloro-7,28,30,32-tetrahidroxil-6-[[(*R*)-4-metil-2-(metilamino)pentanoil]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38*a*-tetradecahidro-8,11:18,21-dieteno-23,36-(iminometano)-22*H*-13,16:31,35-dimeteno-1*H*,13*H*-[1,6,9]oxadiazaciclohexadecino[4,5-*m*][10,2,16]benzoxadiazaciclótetracoseno-26-carboxílico


orienticina D (constituyente secundario):

ácido (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38*aR*)-22-[(3-amino-3-*C*-metil-2,3,6-tridesoxi- $\alpha$ -*L*-arabino-hexopiranosil)oxi]-44-[[2-*O*-(3-amino-3-*C*-metil-2,3,6-tridesoxi- $\alpha$ -*L*-arabino-hexopiranosil)- $\beta$ -*D*-glucopiranosil]oxi]-3-(carbamoilmetil)-19-cloro-7,28,30,32-tetrahidroxil-6-[[(*R*)-2-(dimetilamino)-4-metilpentanoil]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38*a*-tetradecahidro-8,11:18,21-dieteno-23,36-(iminometano)-22*H*-13,16:31,35-dimeteno-1*H*,13*H*-[1,6,9]oxadiazaciclohexadecino[4,5-*m*][10,2,16]benzoxadiazaciclótetracoseno-26-carboxílico

*antibacteriano (vet.)*

A: C<sub>73</sub>H<sub>89</sub>ClN<sub>10</sub>O<sub>26</sub> 111073-20-2D: C<sub>74</sub>H<sub>91</sub>ClN<sub>10</sub>O<sub>26</sub> 112848-46-1

159445-63-3

**pegorgoteinum**

pegorgotein

superoxide dismutase, reaction product with succinic anhydride, esters with polyethylene glycol monomethyl ether  
*enzyme*


pégorgotéine

esters du produit de réaction de l'anhydride succinique sur la superoxyde dismutase et de monoéther méthylique de polyéthylèneglycol  
*enzyme*

pegorgotein

esteres del producto de reacción del anhídrido succínico con la superóxido dismutasa y del monoeter metílico del polietilenglicol  
*enzima*

155773-57-2



m = 118 to 137 ; n = 9 to 13 ; Enz = superoxide dismutase  
m = 118 à 137 ; n = 9 à 13 ; Enz = superoxyde dismutase  
m = 118 a 137 ; n = 9 a 13 ; Enz = superóxido dismutasa

**premafloxacinum**

premafloxacin

1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(3*R*)-3-[(1*S*)-1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid  
*antibacterial (vet.)*

prémáfloxacine


acide 1-cyclopropyl-6-fluoro-8-méthoxy-7-[(3*R*)-3-[(1*S*)-1-(méthylamino)=éthyl]pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique  
*antibactérien (vét.)*

premafloxacino

ácido 1-ciclopropil-6-fluoro-1,4-dihidro-8-metoxi-7-[(3*R*)-3-[(1*S*)-1-(metilamino)etil]-1-pirrolidinil]-4-oxo-3-quinolincarboxílico  
*antibacteriano (vet.)*

C<sub>21</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>4</sub>

143383-65-7

**priliximabum**

priliximab

immunoglobulin G 1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412 κ-chain, dimer  
*immunomodulator*

priliximab

immunoglobuline G1 (anticorps monoclonal homme-souris cm-T412 anti-antigène CD 4 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal homme-souris cm-T412  
*immunomodulateur*

priliximab

inmunoglobulina G 1 (anticuerpo monoclonal hombre-ratón cm-T412 anti-antígeno CD 4 humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hombre-ratón cm-T412  
*immunomodulador*

147191-91-1

**prulifloxacinum**

prulifloxacin

(±)-7-[4-[(*Z*)-2,3-dihydroxy-2-butenyl]-1-piperazinyl]-6-fluoro-1-methyl-4-oxo-1*H*,4*H*-[1,3]thiazeto[3,2-*a*]quinoline-3-carboxylic acid, cyclic carbonate  
*antibacterial*

prulifloxacine


acide (±)-(1*RS*)-6-fluoro-1-méthyl-7-[4-[(5-méthyl-2-oxo-1,3-dioxol-4-yl)=méthyl]pipérazin-1-yl]-4-oxo-4*H*-[1,3]thiazéto[3,2-*a*]quinoléine-3-carboxylique  
*antibactérien*

prulifloxacino

ácido (±)-7-[4-[(*Z*)-2,3-dihidroxi-2-butenil]-1-piperazinil]-6-fluoro-1-metil-4-oxo-1*H*,4*H*-[1,3]tiazeto[3,2-*a*]quinolina-3-carboxílico, carbonato cíclico  
*antibacteriano*

$C_{21}H_{20}FN_3O_6S$ 

123447-62-1



and enantiomer  
et énantiomère  
y enantiómero

**quiflaponum**  
quiflapon

3-(*tert*-butylthio)-1-(*p*-chlorobenzyl)- $\alpha,\alpha$ -dimethyl-5-(2-quinolylmethoxy)=  
indole-2-propionic acid

*5-lipoxygenase-activating protein (FLAP) inhibitor*

quiflapon

acide 3-[1-(4-chlorobenzyl)-3-[(1,1-diméthyléthyl)thio]-5-[(quinoléin-2-yl)=  
méthoxy]-1*H*-indol-2-yl]-2,2-diméthylpropanoïque

*inhibiteur de la protéine activant la 5-lipoxygénase (FLAP)*


quiflapon

ácido 3-(*terc*-butiltio)-1-(*p*-clorobencil)- $\alpha,\alpha$ -dimetil-5-(2-quinolilmetoxi)=  
indol-2-propiónico

*inhibidor de la proteína que activa la 5-lipoxigenasa (FLAP)*

 $C_{34}H_{35}ClN_2O_3S$ 

136668-42-3



**rofleponidum**  
rofleponide

6 $\alpha$ ,9-difluoro-11 $\beta$ ,16  $\alpha$ ,17,21-tetrahydroypregn-4-ene-3,20-dione, cyclic  
(*R*)-16,17-acetal with butyraldehyde

*glucocorticosteroid*

rofléponide

16 $\alpha$ ,17-[(1 *R*)-butylidenedioxy]-6 $\alpha$ ,9-difluoro-11 $\beta$ ,21-dihydroxyprég-4-ène-  
3,20-dione

*glucocorticostéroïde*


rofleponida

6 $\alpha$ ,9-difluoro-11 $\beta$ ,16 $\alpha$ ,17,21-tetrahidroxipregn-4-eno-3,20-diona,(*R*)-16,17-  
acetal cíclico con butiraldehído

*glucocorticosteroide*

$C_{25}H_{34}F_2O_6$ 

144459-70-1

**samixogrelum**

samixogrel

(*E*)-6-[*p*-2-(*p*-chlorobenzenesulfonamido)ethyl]phenyl]-6-(3-pyridyl)-  
5-hexenoic acid  
*platelet aggregation inhibitor*

samixogrel


acide (*E*)-6-[4-[2-[[[4-chlorophényl)sulfonyl]amino]éthyl]phényl]-6-(pyridin-  
3-yl)]hex-5-énoïque  
*antiagrégant plaquettaire*

samixogrel

ácido(*E*)-6-[*p*-2-(*p*-clorobencensulfonamido)etil]fenil]-6-(3-piridil)-  
5-hexenoico  
*inhibidor de la agregación plaquetaria*

 $C_{25}H_{25}ClN_2O_4S$ 

133276-80-9

**sanfetrinemum**

sanfetrinem

(1*S*,5*S*,8*aS*,8*bR*)-1,2,5,6,7,8,8*a*,8*b*-octahydro-1-[(1*R*)-1-hydroxyethyl]-  
5-methoxy-2-oxoazeto[2,1-*a*]isoindole-4-carboxylic acid  
*antibiotic*

sanfétrinem


acide (1*S*,5*S*,8*aS*,8*bR*)-1-[(1*R*)-1-hydroxyéthyl]-5-méthoxy-2-oxo-  
1,2,5,6,7,8,8*a*,8*b*-octahydroazéto[2,1-*a*]iso-indole-4-carboxylique  
*antibiotique*

sanfetrinem

ácido(1*S*,5*S*,8*aS*,8*bR*)-1,2,5,6,7,8,8*a*,8*b*-octahidro-1-[(*R*)-1-hidroxietyl]-  
5-metoxi-2-oxoazeto[2,1-*a*]isoindol-4-carboxílico  
*antibiótico*

$C_{14}H_{19}NO_5$ 

156769-21-0

**saprisartanum**

saprisartan

1-[[[3-bromo-2-[*o*-(1,1,1-trifluoromethanesulfonamido)phenyl]-5-benzofuran-5-yl]méthyl]-4-cyclopropyl-2-éthylimidazole-5-carboxamide  
*angiotensin II receptor antagonist*

saprisartan


1-[[[3-bromo-2-[2-[[[trifluorométhyl)sulfonyl]amino]phényl]benzofuran-5-yl]méthyl]-4-cyclopropyl-2-éthyl-1*H*-imidazole-5-carboxamide  
*antagoniste du récepteur de l'angiotensine II*

saprisartan

1-[[[3-bromo-2-[*o*-(1,1,1-trifluorometansulfonamido)fenil]-5-benzofuranil]metil]-4-ciclopropil-2-etilimidazol-5-carboxamida  
*antagonista del receptor de angiotensina II*

 $C_{25}H_{22}BrF_3N_4O_4S$ 

146623-69-0

**seprilosum**

seprilose

3-*O*-heptyl-1,2-*O*-isopropylidene- $\alpha$ -D-glucufuranose  
*antirheumatic*

séprilose


3-*O*-heptyl-1,2-*O*-(1-méthyléthylidène)- $\alpha$ -D-glucufuranose  
*antirhumatismal*

seprilosa

3-*O*-heptil-1,2-*O*-isopropiliden- $\alpha$ -D-glucufuranosa  
*antirreumático*

 $C_{16}H_{30}O_6$ 

133692-55-4



**setipafantum**

setipafant

6-(*o*-chlorophenyl)-7,10-dihydro-1-methyl-4*H*-pyrido[4',3':4,5]thieno[3,2-*f*]-s-triazolo[4,3-*a*][1,4]diazepine-9(8*H*)-carbox-*p*-anisidide  
platelet-activating factor antagonist

sétipafant


6-(2-chlorophényl)-*N*-(4-méthoxyphényl)-1-méthyl-7,10-dihydro-4*H*-pyrido=[4',3':4,5]thiéno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazépine-9(8*H*)-carboxamide  
antagoniste du facteur activant les plaquettes

setipafant

6-(*o*-clorofenil)-7,10-dihidro-1-metil-4*H*-pírido[4',3':4,5]tieno[3,2-*f*]-s-triazolo[4,3-*a*][1,4]diazepina-9(8*H*)-carboxi-*p*-anisidida  
antagonista del factor activador de las plaquetas

C<sub>26</sub>H<sub>23</sub>ClN<sub>6</sub>O<sub>2</sub>S

132418-35-0

**tagorizinum**

tagorizine

(*E*)-*N*-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-6-methyl-3-pyridine=acrylamide  
antiallergic

tagorizine


(2*E*)-*N*-[4-[4-(diphénylméthyl)pipérazin-1-yl]butyl]-3-(6-méthylpyridin-3-yl)prop-2-énamide  
antiallergique

tagorizina

(*E*)-*N*-[4-[4-(difenilmetil)-1-piperazinil]butil]-6-metil-3-piridinacrilamida  
antialérgico

C<sub>30</sub>H<sub>36</sub>N<sub>4</sub>O

118420-47-6

**talsaclidinum**

talsaclidine

(3*R*)-3-(2-propynyloxy)quinuclidine  
muscarin M<sub>1</sub> receptor agonist


talsaclidine

(3*R*)-3-(prop-2-ynyloxy)-1-azabicyclo[2.2.2]octane  
agoniste des récepteurs muscariniques M<sub>1</sub>

talsaclidina

(3*R*)-3-(2-propiniloxy)quinuclidina  
*agonista de los receptores muscarínicos M<sub>1</sub>*C<sub>10</sub>H<sub>15</sub>NO

147025-53-4



tasosartanum

tasosartan

5,8-dihydro-2,4-dimethyl-8-[*p*-(*o*-1*H*-tetrazol-5-yl)phenyl]benzyl]pyrido=[2,3-*d*]pyrimidin-7(6*H*)-one  
*angiotensin II receptor antagonist*


tasosartan

2,4-diméthyl-8-[4-[2-(1*H*-tétrazol-5-yl)phényl]benzyl]-5,8-dihydro=pyrido[2,3-*d*]pymidin-7(6*H*)-one  
*antagoniste du récepteur de l'angiotensine II*

tasosartan

5,8-dihidro-2,4-dimetil-8-[*p*-(*o*-1*H*-tetrazol-5-ilfenil)benzil]pirido=[2,3-*d*]pirimidin-7(6*H*)-ona  
*antagonista del receptor de angiotensina II*C<sub>23</sub>H<sub>21</sub>N<sub>7</sub>O

145733-36-4



tazarotenum

tazarotene

ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate  
*keratolytic*


tazarotène

6-[2-(4,4-diméthyl-3,4-dihydro-2*H*-1-benzothiïn-6-yl)éthynyl]pyridine-3-carboxylate d'éthyle  
*kératolytique*

tazaroteno

6-[(4,4-dimetiltiocroman-6-il)etini]nicotinato de etilo  
*queratolítico*C<sub>21</sub>H<sub>21</sub>NO<sub>2</sub>S

118292-40-3





**toborinonum**

toborinone

(±)-6-[2-hydroxy-3-(veratrylamino)propoxy]carbostyrl  
*cardiac stimulant*


toborinone

(±)-6-[[[(2*RS*)-3-[(3,4-diméthoxybenzyl)amino]-2-hydroxypropyl]oxy]quinoléin-2(1*H*)-one  
*cardiotonique*

toborinona

(±)-6-[2-hidroxi-3-(veratrilamino)propoxi]carbostiril  
*cardiotónico*C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>

143343-83-3

and enantiomer  
et énantiomère  
y enantiómero**vedaprofenum**

vedaprofen

(±)-4-cyclohexyl-α-methyl-1-naphthaleneacetic acid  
*non-steroidal anti-inflammatory*


védaprofène

acide (*RS*)-2-(4-cyclohexylnaphtalén-1-yl)propanoïque  
*anti-inflammatoire non-stéroïdien*

vedaprofeno

ácido (±)-4-ciclohexil-α-metil-1-naftalenacético  
*antiinflamatorio no esteroideo*C<sub>19</sub>H<sub>22</sub>O<sub>2</sub>

71109-09-6

and enantiomer  
et énantiomère  
y enantiómero**zaleplonum**

zaleplon

3'-(3-cyanopyrazolo[1,5-*a*]pyrimidin-7-yl)-*N*-ethylacetanilide  
*sedative, hypnotic*

zaléplone


*N*-[3-(3-cyanopyrazolo[1,5-*a*]pyrimidin-7-yl)phényl]-*N*-éthylacétamide  
*sédatif, hypnotique*

zaleplon

3'-(3-cianopirazolo[1,5-*a*]primidin-7-il)-*N*-etilacetanilida  
*sedante, hipnótico*

C<sub>17</sub>H<sub>15</sub>N<sub>5</sub>O

151319-34-5

**zanamivirum**

zanamivir

5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid  
*antiviral*

zanamivir


acide (4*S*,5*R*,6*R*)-5-(acétylamino)-4-guanidino-6-[(1*R*,2*R*)-1,2,3-trihydroxypropyl]-5,6-dihydro-4*H*-pyrane-2-carboxylique  
*antiviral*

zanamivir

ácido 5-acetamido-2,6-anhidro-3,4,5-tridesoxi-4-guanidino-D-glicero-D-galacto-non-2-enónico  
*antiviral*

C<sub>12</sub>H<sub>20</sub>N<sub>4</sub>O<sub>7</sub>

139110-80-8

**ziprasidonum**

ziprasidone

5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-2-indolinone  
*antipsychotic*

ziprasidone


5-[2-[4-(1,2-benzisothiazol-3-yl)pipérazin-1-yl]éthyl]-6-chloro-1,3-dihydro-2*H*-indol-2-one  
*psychotrope*

ziprasidona

5-[2-[4-(1,2-bencisotiazol-3-il)-1-piperazinil]etil]-6-cloro-2-indolinona  
*antipsicótico*

C<sub>21</sub>H<sub>21</sub>ClN<sub>4</sub>OS

146939-27-7



## AMENDMENTS TO PREVIOUS LISTS

### Proposed International Nonproprietary Names (Prop. INN): List 64

(WHO Drug Information, Vol. 4, No. 4, 1990)

|       |            |                                                          |
|-------|------------|----------------------------------------------------------|
| p. 14 | liarozolum | <i>replace the CAS registry number by the following:</i> |
|       | liarozole  | 145858-51-1                                              |

### Proposed International Nonproprietary Names (Prop. INN): List 69

(WHO Drug Information, Vol. 7, No. 2, 1993)

|      |               |               |
|------|---------------|---------------|
| p. 4 | <i>delete</i> | <i>insert</i> |
|      | fropenemum    | faropenemum   |
|      | fropenem      | faropenem     |

### Proposed International Nonproprietary Names (Prop. INN): List 71

Dénominations communes internationales proposées (DCI Prop.): Liste 71

Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 71

(WHO Drug Information, Vol. 8, No. 2, 1994)

|      |                      |                                                                                |
|------|----------------------|--------------------------------------------------------------------------------|
| p. 6 | <b>candesartanum</b> |                                                                                |
|      | candesartan          | <i>replace the molecular formula and CAS registry number by the following:</i> |
|      | candésartan          | <i>remplacer la formule brute et le numéro dans le registre de CAS par:</i>    |
|      | candesartan          | <i>reemplázense la fórmula empírica y el número de registro del CAS por:</i>   |
|      |                      | $C_{24}H_{20}N_6O_3$ 139481-59-7                                               |
| p.16 | <b>monteplasmum</b>  |                                                                                |
|      | monteplase           | <i>add the CAS registry number by the following:</i>                           |
|      | montéplase           | <i>insérer le numéro dans le registre du CAS suivant:</i>                      |
|      | monteplasa           | <i>insértese el número del registro del CAS por el siguiente:</i>              |
|      |                      | 156616-23-8                                                                    |

#### Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* ont été publiés avec la liste 71 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.

---

## MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES

**Dénominations communes internationales proposées (DCI Prop.): Liste 64**  
*(Informations pharmaceutiques OMS, Vol. 4, No. 4, 1990)*

|       |            |                                                         |
|-------|------------|---------------------------------------------------------|
| p. 15 | liarozolum | <i>remplacer le numéro dans le registre de CAS par:</i> |
|       | liarozole  | 145858-51-1                                             |

**Dénominations communes internationales proposées (DCI Prop.): Liste 69**  
*(Informations pharmaceutiques OMS, Vol. 7, No. 2, 1993)*

|      |                  |                |
|------|------------------|----------------|
| p. 4 | <i>supprimer</i> | <i>insérer</i> |
|      | fropenemum       | faropenemum    |
|      | fropénem         | faropénem      |

Pour toutes les modifications des **Dénominations communes internationales proposées (DCI Prop.): Liste 71** voyez page 35 sous *AMENDMENTS TO PREVIOUS LISTS*.

---

## MODIFICACIONES A LAS LISTAS ANTERIORES

**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Liste 64**  
*(Información Farmacéutica, OMS, Vol. 4, No. 4, 1990)*

|       |            |                                                       |
|-------|------------|-------------------------------------------------------|
| p. 14 | liarozolum | <i>sustituyase el número de registro del CAS por:</i> |
|       | liarozole  | 145858-51-1                                           |

**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Liste 69**  
*(Información Farmacéutica, OMS, Vol. 7, No. 2, 1993)*

|      |                  |                  |
|------|------------------|------------------|
| p. 4 | <i>suprímase</i> | <i>insértese</i> |
|      | fropenemum       | faropenemum      |
|      | fropenem         | faropenem        |

Para cualquier modificación de las **Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Liste 71** vease página 35, *AMENDMENTS TO PREVIOUS LISTS*.